BTIG analyst Julian Harrison maintained a Hold rating on Morphic Holding (MORF – Research Report) yesterday. The company’s shares closed last Friday at $28.88.
Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Viridian Therapeutics, and CymaBay Therapeutics. According to TipRanks, Harrison has an average return of 14.5% and a 54.03% success rate on recommended stocks.
Currently, the analyst consensus on Morphic Holding is a Moderate Buy with an average price target of $53.80.
See the top stocks recommended by analysts >>
Based on Morphic Holding’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $36.21 million. In comparison, last year the company earned a revenue of $2.06 million and had a GAAP net loss of $30.02 million
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MORF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphic Holding (MORF) Company Description:
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Read More on MORF:
- Morphic initiated with bullish view at Citi, here’s why
- TD Cowen starts ‘only pure-play TL1A company’ Spyre Therapeutics at Outperform
- Morphic price target lowered to $76 from $80 at RBC Capital
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
- Morphic expects cash to fund operations through second half of 2027
